A study links GLP-1 use with bone conditions, but it can’t show the drugs caused them. Weight loss itself may affect bone density.
A newly presented study has raised questions about bone health in people prescribed GLP-1 drugs, but it doesn’t establish that the medicines cause bone problems. The findings are preliminary, and research to date points to another possible explanation: substantial weight loss, whatever the method, can affect the bones.
The study examined five years of medical records for nearly 147,000 adults with type 2 diabetes and obesity. Presented at the American Academy of Orthopaedic Surgeons’ annual meeting in March 2026, it reported an association between GLP-1 use and higher risks of osteoporosis, osteomalacia and gout. The findings have not yet been peer-reviewed.
That association deserves follow-up, but it isn’t a reason on its own to conclude that GLP-1 drugs directly harm bones or joints. The study was observational, which means it identified patterns in health records rather than testing whether the medicines caused the outcomes. Its authors also didn’t specify which GLP-1 drugs people used or the doses recorded.
What the study can and can’t tell us
Medical records don’t always show whether a prescribed medicine was actually taken or continued. People may be unable to start or stay on treatment because of cost, supply problems, insurance coverage or side effects. If records classify people by prescription, rather than confirmed use over time, that can make the relationship between a medicine and an outcome harder to interpret.
The analysis also lacked information about several factors that can influence bone health. Exercise and eating habits matter, as do some medical conditions and other influences, including certain cancers, alcohol use, family history and steroid use. Without accounting for these factors, researchers can’t determine how much each might have contributed to the results.
Marci Laudenslager, an obesity medicine physician at Johns Hopkins who wasn’t involved in the study, says there’s currently no sound scientific evidence that GLP-1 drugs directly raise the risk of osteoporosis, osteomalacia or gout. She and exercise physiologist Kelyssa Hall, of Hospital for Special Surgery, say the findings highlight a question for further study, rather than settle it.
Other research has also examined GLP-1 use and bone health. Taken together, the evidence suggests that some people taking these drugs may experience lower bone density, but the change may relate more to the amount and speed of weight loss than to a direct effect of the medicine.
Why weight loss may affect bones
Bones respond to the physical demands placed on them. When a person loses a substantial amount of weight, the skeleton carries less load during everyday movement. Hall explains that this reduced loading can mean less stimulus for bone to strengthen. Over time, that shift may contribute to lower bone density.
This mechanism isn’t unique to GLP-1 treatment. Significant weight loss through lifestyle changes, medication or surgery can affect the body’s metabolism and bone metabolism. So if bone changes occur during treatment, the medicine itself may not be the direct cause. Researchers still need to work out how weight loss, treatment and other health factors combine.
Osteoporosis involves bones becoming weak and more prone to breaking. Osteomalacia is a condition in which bones soften. Gout, meanwhile, is a form of arthritis that can cause painful, swollen joints. The study reported associations with all three; it didn’t show that every person taking a GLP-1 faces these outcomes, or establish how a particular individual’s risk might change.
Supporting bone health during weight loss
Strength training places demands on muscles and bones and can help support bone density. It can also help preserve muscle during weight loss, which contributes to strength and stability. People who are new to this kind of exercise can discuss a suitable starting point and safe activities with a health care professional, particularly if they have health concerns that affect movement or bone strength.
Eating enough to support overall health is another consideration. GLP-1 drugs can suppress appetite, and some people may find that they’re eating very little. Research links calorie restriction with reduced bone growth and a higher risk of fractures. There isn’t one appropriate energy intake for everyone, so people who are unsure whether they’re getting enough can raise the question with a doctor or registered dietitian.
Protein helps build and maintain both muscle and bone. The amount that makes sense can vary with age and health, including kidney disease. A clinician or dietitian can help someone consider their needs alongside the rest of their diet, including fiber, fluids, healthy fats, vitamins and minerals. Focusing on one nutrient shouldn’t crowd out a balanced range of foods.
The pace of weight loss may also be relevant. Faster, more substantial loss may put greater demands on bone and muscle than gradual change. People who notice that weight is coming off quickly while taking a GLP-1 can discuss the pace with their prescriber. Decisions about medication and treatment belong with the clinician who knows the person’s health history.
When to discuss concerns with a clinician
Bone loss generally develops over time, rather than overnight. That gives clinicians opportunities to consider a person’s risks and identify concerns during their care. Anyone worried about bone health, changes during weight loss or possible treatment effects can bring those concerns to a doctor or pharmacist. People considering obesity treatment may also want care from a clinician with relevant experience.
For now, the 2026 study is an early signal, not proof of harm from GLP-1 drugs. The more useful takeaway is that bone health deserves attention as part of weight-loss care, especially when weight loss is substantial. Further research will help clarify whether particular treatments, the weight change they support, or other factors explain the reported associations.
